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Context: Little is known about long-term quality of life (QoL) of survivors of pediatric differentiated
thyroid carcinoma. Therefore, this study aimed to evaluate generic health-related QoL (HRQoL),
fatigue, anxiety, and depression in these survivors comparedwithmatched controls, and to evaluate
thyroid cancer–specific HRQoL in survivors only.
Design: Survivors diagnosed between 1970 and 2013 at age #18 years, were included. Exclusion
criteria were a follow-up ,5 years, attained age ,18 years, or diagnosis of DTC as a second
malignant neoplasm (SMN). Controls werematched by age, sex, and socioeconomic status. Survivors
and controls were asked to complete 3 questionnaires [Short-Form 36 (HRQoL), Multidimensional
Fatigue Inventory 20 (fatigue), and Hospital Anxiety and Depression Scale (anxiety/depression)].
Survivors completed a thyroid cancer–specific HRQoL questionnaire.
Results: Sixty-seven survivors and 56 controls. Median age of survivors at evaluation was
34.2 years (range, 18.8 to 61.7). Median follow-up was 17.8 years (range, 5.0 to 44.7). On most
QoL subscales, scores of survivors and controls did not differ significantly. However, survivors
had more physical problems (P = 0.031), role limitations due to physical problems (P = 0.021),
and mental fatigue (P = 0.016) than controls. Some thyroid cancer–specific complaints (e.g.,
sensory complaints and chilliness) were present in survivors. Unemployment and more extensive
disease or treatment characteristics were most frequently associated with worse QoL.
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Conclusions:Overall, long-termQoL in survivors of pediatric DTCwas normal. Survivors experienced
mild impairment of QoL in some domains (physical problems, mental fatigue, and various thyroid
cancer–specific complaints). Factors possibly affecting QoL need further exploration. (J Clin
Endocrinol Metab 102: 1218–1226, 2017)
The diagnosis and treatment of childhood cancerconstitute a major life event that may influence
psychosocial functioning and quality of life (QoL) long
after initial treatment has been completed. Pediatric
differentiated thyroid carcinoma (DTC) is a rare malig-
nancy with an excellent survival rate (1, 2). The incidence
of this disease is rising (3, 4). At present there is an in-
creased focus on the long-term consequences of this
disease and its treatment. After initial treatment, which
most often consists of a total thyroidectomy followed by
radioactive iodine (131-I) administration, life-long follow-
up is initiated (5). Moreover, about a third of the pediatric
DTC survivors in The Netherlands have postoperative
complications, including permanent hypoparathyroidism,
which also require medical support (2). Both hypothy-
roidism and hypoparathyroidism have been described as
negatively affecting the QoL of DTC survivors (6, 7).
The available data on QoL in survivors of pediatric
DTC are limited. Most studies evaluate QoL in survivors
of adolescent and adult DTC. QoL in survivors of ado-
lescent DTC was found to be normal compared with
control groups (8, 9). Survivors of adult DTC reported
lower health-related QoL (HRQoL) and higher levels of
fatigue, anxiety, and depression compared with healthy
controls (5, 10–12). For DTC survivors, thyroid
cancer–specific complaints may arise after treatment and
during follow-up. Most long-term survivors of adult
DTC with a median follow-up period of 9.6 years ex-
perienced disease-specific symptoms (13). In survivors of
pediatric DTC, thyroid cancer–specific complaints have
not yet been evaluated.
QoL studies performed in survivors of other childhood
cancers showed conflicting results. QoL varied from no
differences to lower QoL in survivors, compared with a
control or comparison group; this may be explained by
the differences in specific clinical characteristics of the
different types of cancers in which this has been studied
(14–20).
Several specific survivor characteristics may influence
QoL during follow-up. QoL may improve in survivors of
adult DTC after a longer time following diagnosis,
especially$5 years after diagnosis (10, 21). Employment
and a higher educational level were found to be associ-
ated with better QoL in survivors of adult DTC (12, 21,
22). Young adult survivors reported other thyroid
cancer–specific complaints than did older survivors. For
example, young adult survivors reported more scar
complaints, but less voice complaints (22). QoL in DTC
survivors seems to be independent of thyrotropin (TSH)
levels (8, 10).
So far, information is limited on long-term QoL in
survivors of pediatric DTC. Therefore, the first aim of our
study was to evaluate QoL by means of the self-reported
levels of genericHRQoL, fatigue, anxiety, and depression
in adult survivors of pediatric DTC compared with those
of matched controls. The second aim was to evaluate
thyroid cancer–specific HRQoL in adult survivors of
pediatric DTC. Our third aim was to evaluate whether
long-term generic HRQoL, fatigue, anxiety, depression,
and thyroid cancer–specificHRQoLwere associatedwith
survivor, tumor, treatment, or follow-up characteristics.
Materials and Methods
Survivors
Adult survivors of pediatric DTC who participated in a
nationwide follow-up study were asked to participate in this
substudy (2). Inclusion criteria for the nationwide study were:
diagnosis of DTC between January 1970 andDecember 2013 at
the age of #18 years, and treatment in The Netherlands [as
described earlier (2)]. Exclusion criteria for this substudy were:
follow-up ,5 years after diagnosis, attained age ,18 years,
diagnosis of DTC as a second malignant neoplasm, lack of
command of the Dutch language, and 131-I administration
within 3 months before evaluation.
Controls
To include controls, survivors were asked to approach 1 or 2
persons of similar sex and age (65 years of the survivor’s age) at
time of follow-up. The only exclusion criterion for controls was
having a medical history of malignancy. Preferably, peers were
included as controls, trying to match on socioeconomic status. If
thiswas not possible, siblingswere allowed tobematched controls.
Participants
All survivors and controls gave informed consent before
participating in the study. The Institutional Review Board of
the University Medical Center Groningen approved the study
on behalf of all participating institutions.
Medical data
Data on survivor and tumor characteristics (tumor–node–
metastasis classification, histology, and age at diagnosis),
treatment (surgical complications, i.e., hypoparathyroidism and
recurrent laryngeal nerve injury, and cumulative 131-I dose),
and follow-up (follow-up time; outcome, i.e., remission, re-
currence, or persistent disease; and level of TSH suppression
during follow-up) were retrieved frommedical records. Data on
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marital status, job status, and level of education were retrieved
from a questionnaire.
QoL assessment
Generic HRQoL, fatigue, anxiety, and depression question-
naireswere assessed for survivors and controls. The thyroid cancer-
specific HRQoL questionnaire was assessed for survivors only.
The questionnaires delineated below were used to assess QoL.
Short-Form 36
The Short-Form 36 (SF-36) (23) is a 36-item health survey,
validated for the Dutch population (24). This questionnaire
measures self-reported HRQoL on 8 domains: physical func-
tioning, role limitations due to physical problems, bodily pain,
general health, vitality, social functioning, role limitations due
to emotional problems, and mental health. Scores of domains
are presented on a scale from 0 to 100. A higher score indicates
better HRQoL. The scores of the 8 subscales were converted
into the physical and mental component scales by means of the
algorithm of Ware and Kosinski (25), based on Dutch norms
(24). An example of a question in the SF-36 questionnaire is,
“In general, would you say your health is….” Possible answers
are “poor,” “fair,” “good,” “very good,” “excellent.”
Multidimensional Fatigue Inventory 20
TheMultidimensional Fatigue Inventory 20 (MFI-20) (26) self-
report instrument was designed to measure fatigue. Fatigue is
scored on 5 domains: general fatigue, physical fatigue, mental
fatigue, reducedmotivation, and reduced activity. TheMFI-20was
proven to be valid for the Dutch population (26). The total score,
ranging from 20 to 100 (higher scores indicating more fatigue), is
calculated as the sum of the 5 domains, and each domain (range,
4 to 20) is the sum of 4 items. Each domain includes 4 items on
a1- to 5-point scale ranging from“no, that is not true” to“yes, that
is true.” An example of an item is “thinking requires effort.”
Hospital Anxiety and Depression Scale
TheHospital Anxiety and Depression Scale (HADS) (27) is a
14-item self-assessment scale measuring levels of depression and
anxiety. This questionnaire has been validated for Dutch sub-
jects (28). Scores on subscales range from 0 to 21. Scores for the
total scale can range from 0 to 42. A higher score indicates a
higher level of anxiety and/or depression. Answers can be given
on a 4-point Likert scale. For example, for “I feel tense or
‘wound up’,” possible answers are “not at all,” “from time to
time, occasionally,” “a lot of the time,” or “most of the time.”
Thyroid cancer–specific HRQoL
The thyroid cancer–specific HRQoL (THYCA-QoL) (29)
questionnaire was designed to assess treatment- and cancer-
specific side effects of thyroid cancer. For a time frame dealing
with the previous week (except in the case of the sexual interest
item, which refers to the previous 4 weeks), items can be scored
on a 4-point scale ranging from 1 (“not at all”) to 4 (“very
much”). Items are summarized and translated into 7 scales
(neuromuscular, voice, concentration, sympathetic, throat/mouth,
psychological, and sensory problems) and6 single items (problems
with scar, felt chilly, tingling hands/feet, gained weight, headache,
interest in sex). Scales range from 0 to 100. A higher score on this
scale indicates more complaints. An example of a question in the
THYCA-QoL questionnaire is “Have you had a dry mouth?”
Statistical analysis
Characteristics of survivors included in the QoL study were
compared with characteristics of the excluded survivors from
the nationwide study and to the eligible, but not included,
survivors in the QoL study. Characteristics of survivors and
controls were compared to evaluate whether controls were a
good comparison group for the included survivors. Scores on
HRQoL, fatigue, anxiety, and depression of survivors and
matched controls were compared. Scores on thyroid cancer–
specific HRQoL were analyzed using descriptive statistics. As-
sociations between survivor, tumor, treatment, and follow-up
characteristics and scores on QoL were assessed. Single items
of the THYCA-QoL were dichotomized (not at all = no; a little;
quite a bit; and very much = yes) before testing these associations.
Comparisons were made using x2 tests or a Fisher’s exact test
(if .20% of the cells had an expected count of ,5) in case of
categorical variables.Mann–WhitneyU and Kruskal–Wallis tests
were performed because normality and homogeneity assumptions
of dependent variables had been violated. For analyses of possible
correlations between 2 variableswith ordinal scales, the Spearman
rank correlation coefficient was used. The TSH level for each year
of follow-upwas expressed as the geometric mean of the observed
TSH values during that year, as published previously (30).
Missing or unknown values were excluded (listwise deletion)
from analyses or, in case of the 4 questionnaires, imputed using
questionnaire-specific guidelines. For SF-36 and the THYCA-
QoL, scores were imputed when #50% values of the scores for
this subscale were missing. For MFI-20 and HADS, scores were
imputed when$2 values of the subscale were not missing. When
these criteria were not met, survivors or controls were excluded
from analyses of the relevant subscale. IBM SPSS Statistics for
Windows version 23 (IBM, Armonk, NY) was used for statistical
analyses. Differences were considered statistically significant at
P, 0.05. To adjust for the multiple testing, a significance level of
1% (P , 0.01) was used for the tested associations between
survivor, tumor, treatment, and follow-up characteristics andQoL.
Results
Characteristics of survivors of pediatric DTC and
matched controls
Out of 105 survivors participating in the nationwide study
(2), 75 survivorswere eligible for this long-termQoLsubstudy,
67 of whom (89.3%) agreed to participate. Eight survivors
eligible for the QoL study were not included (Fig. 1). As
expected, survivors of the nationwide study, excluded for the
QoL study, and participating survivors in the QoL study
differed in age at evaluation (median 19.1 vs 34.2 years, re-
spectively; P, 0.001) and follow-up duration (median 2.8 vs
17.8 years, respectively; P , 0.001). For all other survivor,
tumor, treatment, or follow-up characteristics, survivors of the
3 groups did not differ (Supplemental Table 1).
Table 1 shows the demographic characteristics of the
survivors and their matched controls. Median age of
survivors at evaluation was 34.2 years (range, 18.8 to
61.7). Most survivors were female (86.6%), were married
or in a relationship (64.2%), andhadapaid job orwere full-
time students (91.0%). Tumor, treatment, and follow-up
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characteristics of survivors are shown in Supplemental
Table 1. Survivors had a median follow-up time of 17.8
years (range, 5.0 to 44.7) after diagnosis. All survivors
underwent a total thyroidectomy and 131-I was adminis-
tered to 97.0%. Of the survivors, 82.1% remained in re-
mission during follow-up. Ten percent had recurrence of
the disease and 7% had persistent disease.
The 67 survivors gathered 59 controls.
Three controls were not included because
matching criteria were not met. The
survivor and control groups did not differ
significantly with respect to sex, age,
marital status, employment/education,
nationality, or completed education
(Table 1). Almost 14% of the controls
were siblings of the survivors.
QoL in adult survivors of pediatric
DTC (vs matched controls)
Table 2 summarizes self-reported
QoL measurements in survivors and
controls. For the subscales of the
questionnaires, survivors had signifi-
cantly lower scores on physical func-
tioning and role limitations due to
physical problems as compared with
controls (P = 0.031 and P = 0.021; lower scores represent
worse HRQoL) [Fig. 2(A) and 2(B)]. Mental fatigue
scores were significantly higher in survivors (P = 0.012;
higher scores represent more fatigue) [Fig. 2(C)]. Scores
on the remaining SF-36 and MFI-20 subscales and all
HADS subscales did not differ significantly between
survivors and controls. In 12 out of 15 subscales on
Figure 1. Flowchart of inclusion of adult survivors of pediatric DTC in the QoL study.
Table 1. Characteristics of Adult Survivors of Pediatric DTC and Matched Controls
Survivors (n = 67) Controls (n = 56) P Value
Sex, n (%) 0.878a
Female 58 (86.6) 49 (87.5)
Male 9 (13.4) 7 (12.5)
Age at evaluation, y 0.431b
Median (range) 34.2 (18.8–61.7) 34.0 (19.4–60.2)
Age at diagnosis, y n.a.
Median (range) 15.8 (7.9–18.8) —
Follow up duration, y n.a.
Median (range) 17.8 (5.0–44.7) —
Nationality, n (%) n.a.
Dutch 67 (100) 56 (100)
Marital status, n (%) 0.129a
Relationship 43 (64.2) 43 (76.8)
No relationship 24 (35.8) 13 (23.2)
Completed education, n (%) 0.128a
Low level 16 (23.9) 6 (10.7)
Medium level 25 (37.3) 21 (37.5)
High level 26 (38.8) 29 (51.8)
Employment, n (%) 0.743a
Employed or full-time student 61 (91.0) 50 (89.3)
Unemployed and no full-time student 6 (9.0) 6 (10.7)
Relationship with survivor, n (%) n.a.
Peer — 48 (85.7)
Sibling — 8 (14.3)
Abbreviation: n.a., not applicable.
ax2 Test.
bMann–Whitney U test.
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generic HRQoL, fatigue, anxiety, and depression, the
interquartile range of scores was larger for survivors
than for controls; for none of the 15 subscales was the
interquartile range of scores for controls larger than that
for the survivors. For the component scales, scores on
the physical component scale were significantly lower in
survivors compared with controls (P = 0.024; lower
scores represent worse HRQoL). Scores of other sum-
mary scales (mental component scale, total MFI-20,
and total HADS scores) did not differ significantly be-
tween survivors and controls. Scores of survivors with a
second malignant neoplasm (SMN) are reported in
Supplemental Table 2. Three survivors developed a SMN
after DTC. Scores of QoL of the 2 women diagnosed with
breast cancer were similar compared with the survivors
that were not diagnosed with a SMN. For 1 woman
diagnosed with a high-grade cervical intraepithelial
neoplasia, QoL scores were lower compared with the
survivors that were not diagnosed with a SMN after
DTC. Siblings of survivors did not differ significantly
from nonsiblings in scores on questionnaires (data not
shown). For thyroid cancer–specific QoL, scores of
Table 2. QoL in Adult Survivors of Pediatric DTC and Matched Controls
Questionnaire Survivors (n = 67) Controls (n = 56) P Value
Survivors vs controls
SF-36, median (p25, p75)
Physical functioning 95 (85, 100)a 100 (95, 100)b 0.031c
Role limitations due to physical problems 100 (75, 100)a 100 (100, 100)b 0.021c
Bodily pain 84 (72, 100)a 100 (74, 100)d 0.104
Social functioning 88 (63, 100) 100 (81, 100) 0.065
Mental health 84 (72, 92)a 84 (76, 92) 0.723
Role limitations due to emotional problems 100 (67, 100)a 100 (67, 100)b 0.711
General health perceptions 72 (57, 87)a 77 (67, 89) 0.231
Vitality 65 (50, 78)a 70 (60, 80) 0.194
Mental component summary scale 54 (41, 56)e 53 (47, 56)b 0.961
Physical component summary scale 53 (47, 57)e 57 (53, 59)b 0.024c
MFI-20, median (p25, p75)
General fatigue 10 (8, 15) 9 (5, 12) 0.075
Physical fatigue 8 (5, 12) 6 (4, 10) 0.083
Reduced activity 8 (5, 11) 8 (5, 11) 0.613
Reduced motivation 6 (4, 9) 6 (4, 9) 0.879
Mental fatigue 9 (5, 15) 7 (4, 10) 0.012c
Total 41 (31, 57) 36 (27, 54) 0.129
HADS, median (p25, p75)
Anxiety 4 (2, 9) 3 (2, 6) 0.317
Depression 1 (0, 4) 1 (0, 3) 0.964
Total 6 (2, 11) 4 (3, 9) 0.392
Survivors only
THYCA-QoL scales, median (p25, p75)
Neuromuscular 11 (0, 22)
Voice 0 (0, 17)
Concentration 0 (0, 17)
Sympathetic 0 (0, 17)
Throat/mouth 11 (0, 22)
Psychological 8 (0, 17)
Sensory 17 (0, 33)
THYCA-QoL single items, n (%) No A Little Quite a Bit Very Much
Problems with scara 56 (84) 8 (12) 2 (3) 0 (0)
Felt chilly 39 (58) 13 (19) 9 (13) 6 (9)
Tingling hands/feet 42 (63) 19 (28) 5 (8) 1 (2)
Gained weight 47 (70) 16 (24) 3 (5) 1 (2)
Headache 34 (51) 29 (43) 2 (3) 1 (2)
Interested in sex 8 (12) 37 (55) 21 (31) 1 (2)
For SF-36, higher scores indicate a better HRQoL; subscales range from 0 to 100. For MFI-20, higher scores indicate more fatigue; subscales range from 4
to 20; the total scale ranges from 20 to 100. For HADS, higher scores indicate higher levels of anxiety and/or depression; subscales range from 0 to 21;
the total scale ranges from 0 to 42. For THYCA-QoL, a higher score indicates more symptoms; subscales range from 0 to 100.
an = 66 because 1 survivor filled in the questionnaire erroneously.
bn = 54 because 2 controls filled in the questionnaire erroneously.
cP , 0.05. Scores on the SF-36, MFI-20, and HADS were compared using the Mann–Whitney U test.
dn = 53 because 3 controls filled in the questionnaire erroneously.
en = 65 because 2 survivors filled in the questionnaire erroneously.
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survivors are shown in Table 2 and Fig. 2(D). Most
frequently reported were neuromuscular, throat/mouth,
psychological, and sensory complaints, feeling chilly, and
headache.
Characteristics associated with QoL in adult
survivors of pediatric DTC
Characteristics that were possibly associated with
QoL in adult survivors of pediatric DTC are shown in
Supplemental Table 3. Male survivors reported higher
levels of reduced motivation and more depression than
did females (P = 0.007 and P = 0.009). Unemployment was
associated with lower scores on physical functioning and
the physical component scale (P = 0.005 andP = 0.003) and
higher levels of general fatigue, physical fatigue, and total
fatigue (P = 0.009, P = 0.009, and P = 0.004, respectively).
Treatment with a higher cumulative dose of 131-I was
associatedwithmore complaints of headache (P = 0.006).
Survivors with recurrent or persistent disease and sur-
vivors with a higher level of TSH suppression reported
more complaints about the scars in their necks (P, 0.001
and P = 0.002).
Marital status at follow-up, educational level, age at
follow-up, all tumor characteristics (i.e., age at diagnosis,
tumor–node–metastasis stage, and histology), surgical
complications (permanent hypoparathyroidism and re-
current laryngeal nerve injury), and follow-up duration
showed no significant associations with QoL (HRQoL,
fatigue, anxiety, depression, and/or thyroid cancer–
specific HRQoL).
Discussion
In the present study, we focus on long-term QoL in adult
survivors of pediatric DTC, and our results show overall
normal HRQoL, fatigue, anxiety, and depression in these
survivors compared with matched controls. This normal
QoL is similar to that found in studies performed in sur-
vivors of adolescent DTC (8, 9). Although survivors re-
ported more physical problems, role limitations due to
physical problems, and mental fatigue, the overall scores of
survivors on these domains were still within the normal
range. Thyroid cancer–specific complaints were present in
some survivors, but most survivors reported relatively few
or no complaints [Table 2; Fig. 2(D)]. Another reflection of
the normal QoL of the survivors is their full participation
in society, exemplified in most of these survivors by high
employment and relationship rates and an educational level
comparable to matched controls. Thereby, most (88%) of
the survivors reported to have an interest in sex.
Remarkably, the overall QoL in survivors of pediatric
DTC seems to be better than the QoL of survivors di-
agnosed with DTC at older ages. HRQoL, fatigue,
Figure 2. QoL scores in survivors of pediatric DTC. (A–C) Scores of
survivors vs controls. (A) Physical functioning (SF-36, HRQoL) scores
of survivors of vs matched controls. Scale ranges from 0 to 100.
A higher score indicates a better QoL. (B) Limitations in role
functioning due to physical health (SF-36, HRQoL) scores of survivors
vs matched controls. Scale ranges from 0 to 100. A higher score
indicates a better QoL. (C) Mental fatigue (MFI-20, fatigue) scores of
survivors vs matched controls. Scale ranges from 4 to 20. A higher
score indicates a worse QoL. (D) Scores of survivors only. Scores of
survivors on neuromuscular, throat/mouth, psychological, and
sensory complaints are shown. Scales range from 0 to 100. A
higher score indicates a worse QoL.
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anxiety, and depression were reported as worse in both
short- and long-term survivor studies in adult DTC
compared with controls (10, 11). Additionally, survivors
of (young) adult DTC seem to experience more severe
thyroid cancer–specific complaints than do survivors of
pediatric DTC (5, 13, 22).
Although overall QoL is normal in pediatric DTC
survivors compared with controls, physical problems
seemed to be relatively more prominent in the survivor
group compared with controls. The impaired physical
functioning observed in survivors of pediatric DTC has
been described previously in other childhood cancer
survivors (18, 19). Also in adult DTC survivors, the
largest differences in scores between survivors and the
general population were observed for physical com-
plaints and complaints of fatigue (11).
Besides physical obstacles, survivors in the present study
experienced mental constraints, in particular mental fa-
tigue, entailing the inability to stay concentrated. Husson
et al. (5) proposed that (mental) fatigue in survivors of
(adult) DTC might be due to a suboptimal TSH level
suppression target or could otherwise be explained by the
presence of cancer-related fatigue (31). The present data
provided no support for a possible relationship between
TSH levels and fatigue, which is consistent with findings
in DTC survivors diagnosed at older ages (8, 10).
Normal anxiety and depression levels as we found in
the survivors of pediatric DTC were similar to the re-
ported similar levels of emotional distress found in sur-
vivors of other childhood cancers (e.g., acute lymphatic
leukemia, renal tumor, non-Hodgkin lymphoma, and
other types of cancer) and controls (32).
Survivors reported neuromuscular, throat/mouth, psy-
chological, and sensory problems to be most present in the
symptom scale items. Headache and feeling chilly were
reported most frequently in the single items. Complaints
most often reported in survivors of adult DTC were
sympathetic complaints, neuromuscular complaints, and
complaints of fatigue (13). Physicians underestimate the
incidence of several thyroid cancer–specific complaints in
survivors (21). For example, although 40%of the survivors
reported voice problems, for only 15% of the survivors,
recurrent laryngeal nerve injury was reported in their
medical records (Supplemental Table 1). Because only 3
survivors were diagnosed with a SMN after DTC (Sup-
plemental Table 2), general conclusions regarding QoL in
this specific group of survivors cannot be drawn.
QoL is more variable in survivors compared with
controls, as shown by the wider distribution toward
worseQoL in survivors [Fig. 2(A–C)]. It would be of great
value to be able to portend QoL (variability) based on
predictors. Therefore, the present study evaluated
whether long-term generic HRQoL, fatigue, anxiety,
depression, and thyroid cancer–specific HRQoL were
associated with survivor, tumor, treatment, or follow-up
characteristics. Of all possible predictors of QoL, un-
employment was most frequently associated with worse
QoL on many domains. However, the retrospective de-
sign of the study does not allow us to make statements
regarding the causality of this impairment. This means
that employment could influence QoL or vice versa.
Socioeconomic factors could play a role in the level of
QoL, as has been described previously in studies evalu-
ating QoL in survivors of adult DTC (21, 22). Adddi-
tionally, we found evidence for a more impaired QoL
among survivors undergoingmore extensive treatment or
survivors with a more extended disease. Survivors with a
worse outcome may report more complaints due to their
more active disease and treatment. Lower QoL in female
survivors of DTC compared withmale survivors has been
reported by several authors (21, 22). However, owing to
the limited number of male survivors in the present study,
conclusions regarding associations between sex and QoL
could not be drawn. Adverse late effects on physical
functioning have been described after administration of
131-I to survivors of adult DTC (33, 34). An association
between worse QoL and higher doses of 131-I in survi-
vors of adult DTC has previously been described (35).
The present data on survivors of pediatric DTC also show
an association between higher cumulative doses of 131-I
andworseQoL. In contrast, QoL in survivors of pediatric
DTC was shown to be independent of other tumor or
treatment characteristics, which confirms findings of
studies in survivors of adult DTC (10, 21). Survivors of
adult DTC showed an increasing QoL .5 years after
diagnosis (21). The normal QoL in the present survivors
may be explained by their long-term follow-up, but the
present results do not confirm this hypothesis: a longer
follow-up period was not associated with better QoL.
Thepresent studyhasboth strengths and limitations.This
study considers the QoL of adult survivors of both pediatric
and adolescent DTC. Moreover, survivors were compared
with sex-, age-, and socioeconomic-matched controls. Be-
cause of the cross-sectional design of the study $5 years
after diagnosis, short-term QoL was not evaluated. Because
pediatric DTC is uncommon, gathering a larger group of
survivors is difficult.Owing to nonnormally distributed data
and the limited number of survivors included in this study,
multivariable regression or stratified analysis was not fea-
sible. To make more conclusive statements, international
collaboration in prospective studies assessing QoL in pe-
diatric DTC survivors is urgently needed. Moreover, to
identify characteristics that predict QoL, longitudinal pro-
spective studies would be more appropriate.
Finally, the results of this study were based only on
quantitative data. Combining quantitative and qualitative
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elements to assessQoL in survivors of pediatric DTC could
help to evaluate perceived physical andmental limitations
and parameters that could in turn predict QoL more
clearly; such methodology has also been applied in
studies of survivors of adult DTC (36).
To identify vulnerable childhood cancer survivors
early and offer them the care they need, regular mea-
surement of QoL parameters should be implemented
during follow-up. This is in accordance with Dutch
evidence-based guidelines for follow-up of childhood
cancer survivors (37). Additionally, measurements at
baseline and during treatment should also be performed
to evaluate individual alterations in QoL. In our opinion,
follow-up regarding monitoring QoL is necessary in
survivors of pediatric DTC.
In conclusion, this study shows that, in general, long-
term adult survivors of pediatric DTC function well in
society, with relatively good HRQoL and levels of fa-
tigue, anxiety, and depression that are similar to matched
controls. Various thyroid cancer–specific complaints
were present (e.g., sensory complaints, headache, and
chilliness), but mostly in mild forms. However, physical
problems andmental fatigue seemed to be relatively more
prominent in the survivor group compared with controls.
Thereby, scores on QoL in survivors are widespread,
indicating individual differences between survivors.
Factors most frequently associated with worse QoL were
unemployment and more extensive disease or treatment
characteristics. These predictors will have to be further
explored in future studies. We recommend evaluating
changes in the QoL of individual pediatric DTC patients
from diagnosis to long-term follow-up, using a prospective
screening program to be able to provide early and in-
dividualized care to prevent long-term alterations in QoL.
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